JPRN-jRCT2080220085未知3 期
Multicenter, double-blind randomized, controlled study for the treatment of involutional osteoporosis
ONO PHARMACEUTICAL CO.,LTD.0 个研究点开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 45age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Patients of female aged 45 years or older with documented involutional osteoporosis according to the diagnostic criteria for primaly osteoporosis
排除标准
- 未提供
研究者
相似试验
未知
3 期
Multicenter, double-blind randomized, controlled study for the treatment of involutional osteoporosisJPRN-jRCT2080220084ONO PHARMACEUTICAL CO.,LTD.
进行中（未招募）
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-FRHEXAL Biotech ForschungsGmbH300
进行中（未招募）
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-ATHEXAL AG300
进行中（未招募）
不适用
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsEUCTR2007-001906-26-BGHEXAL Biotech ForschungsGmbH300
进行中（未招募）
1 期
Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patientsanemia associated with chronic renal insufficiency in predialysis patientsMedDRA version: 9.1Level: LLTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-001906-26-SKHEXAL Biotech ForschungsGmbH300